Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi最新文献

{"title":"[Application of the variant allele frequency of myeloid-associated gene mutations in myelodysplastic syndrome].","authors":"M Y Shang, L Su","doi":"10.3760/cma.j.cn121090-20240806-00293","DOIUrl":"10.3760/cma.j.cn121090-20240806-00293","url":null,"abstract":"<p><p>Myelodysplastic syndrome (MDS) is a heterogeneous clonal myeloid malignancy with a variable prognosis. Some myeloid-related gene alterations have been found to be associated with the diagnosis and prognosis of MDS. As a result, multiple myeloid-related gene mutations have been added to International Working Group for Prognosis in MDS (IWG-PM) and other MDS prognosis evaluation systems as diagnostic and prognostic indications. Further research using the variable allele frequency (VAF) detection technique demonstrated that myeloid-related genes evolve dynamically during the course of MDS with some regularity. Furthermore, significant relevance have been found between the VAF evolution of particular myeloid-related genes and MDS subtypes, risk classification, and prognosis. This article provides an overview of the application of VAF of myeloid-related gene mutations in MDS research, highlighting the critical role of gene mutation VAF in MDS subtype categorization, risk stratification, and therapy response assessment.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"372-376"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Develop and assessment of a predictive model for the first-course efficacy of acute myeloid leukemia].","authors":"F Zhu, Y L Zhou, Y Zhang, L P Mao, D Zhou, L Y Ma, C M Yang, W J Yu, X N Ye, J Y Wei, H T Meng, M Yang, W Y Mai, J J Qian, Y L Ren, Y J Lou, J Huang, G X Xu, W Z Xie, H Y Tong, H F Wang, J Jin","doi":"10.3760/cma.j.cn121090-20240816-00305","DOIUrl":"10.3760/cma.j.cn121090-20240816-00305","url":null,"abstract":"<p><p><b>Objective:</b> To identify the relevant factors for the first-course remission of acute myeloid leukemia (AML) and to develop a predictive model as well as assess its predictive capability. <b>Methods:</b> Clinical data of 749 patients newly diagnosed with AML admitted to the Department of Hematology, the First Affiliated Hospital, Zhejiang University, School of Medicine from January 1, 2019, to April 30, 2023, were collected and randomly divided into training and validation sets. Multivariate logistic regression analysis was conducted to determine variables associated with complete remission in the first course of induction therapy, and a predictive model was established based on these variables. The receiver operating characteristic (ROC) curve of the predictive model was plotted, and the area under the curve (AUC) was calculated. <b>Results:</b> The indicators predicting the first remission course included peripheral blood white blood cell count during onset, CBF::MYH11 fusion gene, CEBPA bZIP region mutation, myelodysplastic syndrome-related gene mutation, and induction chemotherapy regimen selection as independent factors for the first remission course. The model's area under the training and validation curves was 0.738 (95% <i>CI</i>: 0.696-0.780) and 0.726 (95% <i>CI</i>: 0.650-0.801), respectively. The Hosmer-Lemeshow test results yielded <i>P</i>-values of 0.993 and 0.335, respectively. <b>Conclusion:</b> In this study, the developed model demonstrates a strong predictive capability for the efficacy of the first course of patients with AML, providing valuable guidance to clinicians in assessing patient prognosis and selecting appropriate treatment strategies.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"336-342"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety of zanubrutinib in treating refractory/relapsed warm autoimmune hemolytic anemia].","authors":"S P Shen, C Yang, M Chen, B Han","doi":"10.3760/cma.j.cn121090-20241110-00442","DOIUrl":"10.3760/cma.j.cn121090-20241110-00442","url":null,"abstract":"<p><p>This retrospective analysis included 10 patients with relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) who received zanubrutinib (treatment course: 3-6 months) and completed at least 3 months of follow-up at Peking Union Medical College Hospital from July 2022 to January 2024. The cohort included two male and eight female patients with a median age of 63 years (range: 36-76), who had received a median of 9 months (range: 3-22) of previous therapies. At 1-month, 3-month, and final follow-up (median 7 months), the overall response (OR) rates were 30%, 60%, and 60%, with corresponding complete response (CR) rates of 20%, 40%, and 40%, respectively. The median time to achieve a response was 2 months (range: 1-2) among the responders. No disease relapse or clonal progression was documented during follow-up. Treatment-related adverse events occurred in 30% of the patients (all grade 1-2 reversible events). One responder died of infectious multiple organ failure at 8 months after treatment initiation. Our results indicate that zanubrutinib provides rapid amelioration of anemia with manageable short-term safety in patients with relapsed/refractory wAIHA.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"355-358"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on the diagnosis and treatment of plasmablastic lymphoma (2025)].","authors":"","doi":"10.3760/cma.j.cn121090-20241213-00566","DOIUrl":"10.3760/cma.j.cn121090-20241213-00566","url":null,"abstract":"<p><p>Plasmablastic lymphoma (PBL) originates from activated B cells in the terminal differentiation stage of the germinal centers. PBL is characterized by unique clinical, pathological, and molecular features, demonstrating high aggressiveness and poor prognosis. It exhibits a low incidence and a challenging diagnosis, with a lack of standardized treatment protocols. To improve the understanding of PBL among clinical physicians in China and enhance diagnostic and treatment levels, which will facilitate the initiation of multicenter clinical research, the Lymphocyte Disease Group of the Hematology Division of the Chinese Medical Association and the Lymphoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO) have organized relevant experts to formulate this consensus.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"295-301"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Comparison of the efficacy of continuous VA chemotherapy and I/HDAC consolidation in postremission therapy for acute myeloid leukemia fit for standard chemotherapy].","authors":"L Sun, P P Zhang, S M Ren, N Zhou, L Y Li, Z Z Wang, W G Cui, F Yang, J M Luo, L Yang","doi":"10.3760/cma.j.cn121090-20240529-00198","DOIUrl":"10.3760/cma.j.cn121090-20240529-00198","url":null,"abstract":"<p><p><b>Objective:</b> To compare the efficacy and safety of continuous venetoclax combined azacitidine (VA) chemotherapy and intermedium/high-dose cytarabine (I/HDAC) consolidation in patients with acute myeloid leukemia (AML) fit for standard chemotherapy (transform from UNFIT) . <b>Methods:</b> Clinical data of patients who were fit for standard chemotherapy were collected among those with AML who underwent VA induction in the Department of Hematology, the Second Hospital of Hebei Medical University. The overall survival (OS), relapse-free survival (RFS), event-free survival (EFS), and incidence of adverse events were analyzed retrospectively. <b>Results:</b> This study enrolled 69 patients, consisting of 46 cases in the VA group and 23 cases in the I/HDAC group. We revealed the following. ① The median OS, RFS, EFS were 26.18, 24.69, 20.34 months in the VA group, and 34.14, 30.99, 28.42 months in the I/HDAC group, respectively, with no statistically significant difference (all <i>P</i>>0.05). Median OS of patients who underwent I/HDAC consolidation with European Leukemia Net (ELN) favorable-risk, positive measurable residual disease (MRD), wild type FLT3, or IDH1/2 mutation was significantly longer than those who received VA (<i>P</i><0.05). ②Adverse events rate of grade 3 - 4 neutropenia, grade 3 - 4 thrombocytopenia, and bacteremia were significantly lower in the VA group than in the I/HDAC group (<i>P</i><0.05) . <b>Conclusions:</b> I/HDAC consolidation was more likely to help get survival benefits for patients with ELN favorable-risk, positive MRD, wild type FLT3, or IDH1/2 mutation. Continuous VA chemotherapy exhibited superior safety than I/HDAC consolidation.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"343-348"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Delayed physical growth and related factors in pediatric patients with transfusion-dependent thalassemia].","authors":"Z X Kuang, J Y Zhao, X Yu, J Xu, Z Gao, Y J Liu, A N Wang, J Dong, H Pan, L L Zhang, L W Fang, G B Wu, X L Li, J Shi, L Xu, W J Xie","doi":"10.3760/cma.j.cn121090-20240903-00333","DOIUrl":"10.3760/cma.j.cn121090-20240903-00333","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objectives:&lt;/b&gt; To investigate the physical growth status of pediatric patients with transfusion-dependent thalassemia (TDT) and analyze the effects of treatment-related and socioeconomic factors on physical growth. &lt;b&gt;Methods:&lt;/b&gt; Based on the specialized thalassemia database from gene therapy clinical research at the Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, we collected data on height and weight development, family economic status, and medical records of 338 pediatric patients with TDT from October 2023 to May 2024. The length/height-for-age and body mass index (BMI) -for-age were classified based on the Growth Standard for Children under 7 Years of Age, Standard for Height Level Classification among Children and Adolescents Aged 7-18 Years, and Dietary Guidelines for Chinese Residents. Logistic regression analysis was conducted to assess the effects of family economic status and disease-related treatment on length/height-for-age and BMI-for-age. &lt;b&gt;Results:&lt;/b&gt; Among the 338 patients, 118 were children and 220 were adolescents (192 males and 146 females), with a median age of 12 years (range: 0.8-18) and a median diagnosis duration of 10.3 years (range: 0.5-17.9). Subtypes included α-thalassemia [21 cases (6.2%) ], β-thalassemia [288 cases (85.2%) ], and combined αβ-thalassemia[29 cases (8.6%) ]. The monthly household income of patients was concentrated in 3 000-5 000 yuan (39.9%) and 5 001-10 000 yuan (34.9%), whereas 67.2% of the families had monthly medical expenses of &lt;3 000 yuan. Of the patients, 75.5% received their first transfusion before 1 year of age. The proportions of children and adolescents with pretransfusion hemoglobin (HGB) of ≤70 g/L were 4.2% and 6.4%, respectively. Adolescents demonstrated significantly higher rates of transfusion frequency of &lt;4 weeks/session, monthly red blood cell infusion of &gt;2 U, serum ferritin (SF) of ≥5 000 μg/L, iron chelation therapy, and splenectomy compared with children (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). Of the 338 patients, 26.0%, 22.8%, and 8.9% demonstrated stunted growth, underweight, and concurrent stunted growth with underweight, respectively. No significant difference was observed in the stunted growth rates between children (22.9%) and adolescents (27.7%) (&lt;i&gt;P&lt;/i&gt;=0.402). However, the underweight rate in adolescents (26.8%) was significantly higher than that in children (15.3%) (&lt;i&gt;P&lt;/i&gt;=0.023). The multivariate analysis determined the following risk factors for stunted growth: monthly household income of &lt;10 000 yuan (5 001-10 000 yuan: &lt;i&gt;OR&lt;/i&gt;=5.49, 95% &lt;i&gt;CI&lt;/i&gt;: 1.48-35.76; 3 000-5 000 yuan: &lt;i&gt;OR&lt;/i&gt;=6.87, 95% &lt;i&gt;CI&lt;/i&gt;: 1.88-44.60; &lt;3 000 yuan: &lt;i&gt;OR&lt;/i&gt;=9.29, 95% &lt;i&gt;CI&lt;/i&gt;: 2.20-64.77), pretransfusion HGB of ≤70 g/L (&lt;i&gt;OR&lt;/i&gt;=3.25, 95% &lt;i&gt;CI&lt;/i&gt;: 1.07-10.18), and SF of ≥5 000 μg/L (&lt;i&gt;OR&lt;/i&gt; = 3.04, 95% &lt;i&gt;CI&lt;/i&gt;: 1.20-7.70). Longer diagnostic duration was associated with underweight (&lt;i&gt;OR&lt;/i&gt;=1.10, 9","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"328-335"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on standard procedures for the outpatient management of patients with multiple myeloma (2025)].","authors":"","doi":"10.3760/cma.j.cn121090-20250123-00044","DOIUrl":"10.3760/cma.j.cn121090-20250123-00044","url":null,"abstract":"<p><p>With the development of new drugs and treatments, the survival of patients with multiple myeloma (MM) is significantly prolonged, and MM treatment has entered the stage of chronic disease management. To assist in MM management, the Plasma Cell Disease Group of the Chinese Society of Hematology and the Hematology Committee of the Chinese Medicine Education Association prepared this expert consensus. It provides recommendations on the conditions of establishing outpatient management, standards and processes of patient treatment, outpatient follow-up management, and patient education. This consensus aims to establish and optimize the outpatient management model of MM treatment, enhance the efficacy of patient management and follow-up, and thereby to establish a more convenient diagnosis and treatment model.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"284-288"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Nonspecific peripheral T cell lymphoma combined with pure red cell aplasia: a case report and literature review].","authors":"X Y Zhang, Y Y Zheng, D G Fan, J F Zhong, S X Wu","doi":"10.3760/cma.j.cn121090-20240809-00297","DOIUrl":"10.3760/cma.j.cn121090-20240809-00297","url":null,"abstract":"<p><p>Nonspecific peripheral T-cell lymphoma (PTCL-NOS) combined with pure red cell aplasia (PRCA) is reported by only few in China. This article described a patient with PTCL-NOS who presented with severe anemia as the initial symptom, accompanied by multiple lymphadenopathy. Laboratory tests confirmed decreased red blood cell count and reticulocyte proportion, markedly reduced bone marrow red blood cell proliferation, and markedly increased proportion of bone marrow CD3(+)CD8(+) T lymphocytes. On lymph node pathology examination, immunohistochemistry was consistent with PTCL-NOS, with positive TCRβ gene rearrangement. First-line chemotherapy with four courses of ECHOP regimen led to significant reductions in lymph node size, partial remission on whole-body computed tomography evaluation, normalization of hemoglobin and bone marrow hematopoietic erythroid proliferation, and absence of CD3(+)CD8(+) T lymphocytes in bone marrow. Currently, the patient remains to have good prognosis with maintenance oral lenalidomide.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"359-362"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144161155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Correlation between complement deposition levels on blood cells and clinical biomarkers in patients with paroxysmal nocturnal hemoglobinuria].","authors":"M L Zhang, X Wang, C Yang, M Chen, B Han","doi":"10.3760/cma.j.cn121090-20240717-00265","DOIUrl":"10.3760/cma.j.cn121090-20240717-00265","url":null,"abstract":"<p><p><b>Objective:</b> To explore the complement deposition levels on blood cell surfaces in patients with paroxysmal nocturnal hemoglobinuria (PNH) and evaluate their association with clinical manifestations. <b>Methods:</b> This study enrolled patients with PNH, who had not been treated with complement inhibitors and appeared at Peking Union Medical College Hospital from February 2021 to February 2023. The clinical information of participants was retrospectively recorded, and peripheral blood samples were collected. Gender- and age-matched normal controls (NC) were recruited accordingly. C5b-9, C3, C4b, and factor B (FB) deposition levels on peripheral red blood cells, white blood cells, and platelets were detected with flow cytometry. The correlation between complement deposition levels and clinical symptoms was analyzed. <b>Results:</b> This study involved 73 patients with PNH, including 42 (57.5%) males, with a median age of 36 (range: 14-76) years. 16 matched NC were collected. Among patients with PNH, 36 (49.3%) had classical PNH and 37 (50.7%) had aplastic anemia-PNH syndrome. Thromboembolic events (TEE) occurred in 18 (24.7%) patients. The median HGB, absolute reticulocyte count (Ret), and lactate dehydrogenase of PNH patients were 76 (37-116) g/L, 181.0 (45.9-495.8) ×10(9)/L, and 1 875 (377 - 5 509) U/L, respectively. The median number of Flaer-negative white blood cells was 94.0% (13.0% - 99.9%) ; the median CD59 negative red blood cells was 46.7% (9.0% - 93.0%). The deposition of C5b-9, C3, C4b, and FB on red blood cells, white blood cells, and platelets in patients with PNH was significantly higher than that in NC (all <i>P</i><0.05). C5b-9 deposition level was significantly higher than that of C3, C4b, and FB on all three blood cell lineages in PNH patients (all <i>P</i><0.01). The deposition of all complement fragments on red blood cells was significantly lower than that on white blood cells and platelets (all <i>P</i><0.01). C5b-9 deposition on red blood cells was positively correlated with Ret in PNH patients (<i>P</i>=0.005). C3 (<i>P</i>=0.001) and C4b (<i>P</i>=0.017) deposition levels on white blood cells and C3 deposition on platelets (<i>P</i>=0.002) in patients with TEE history were lower than those without. <b>Conclusions:</b> C5b-9, C3, C4b, and FB deposition levels on all three blood cells in patients with PNH were higher than NC. Increased C5b-9 on red blood cells may indicate active hemolysis. Reduced C3 and C4b levels on white blood cells and low C3 deposition on platelets may indicate TEE risk.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"314-320"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Treatment challenges and optimal management of classical Hodgkin's lymphoma].","authors":"J Q Mi, Y Fang, W Y Yu, Q Q Cai","doi":"10.3760/cma.j.cn121090-20240906-00338","DOIUrl":"10.3760/cma.j.cn121090-20240906-00338","url":null,"abstract":"<p><p>The cure rate of patients with classical Hodgkin's lymphoma (cHL) has significantly improved and the mortality rate has decreased with the advancement of chemotherapy and radiotherapy, especially the application of combined radio-chemotherapy. However, some patients still face relapse or refractory issues, as well as the risk of death due to treatment-related adverse reaction. Treatment has fully entered the era of targeted therapy in recent years, with the deepening research on cHL. Novel drugs, represented by targeted CD30 antibody-drug conjugates and immune checkpoint inhibitors, have further improved the prognosis of patients with newly diagnosed and relapsed/refractory cHL. This study aims to determine the mechanism of achieving comprehensive optimization management of cHL in the new era of drugs, improve patient prognosis, enhance therapeutic efficacy, and reduce the occurence of adverse reactions.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"364-371"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144161194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}